Phenyl-tetrazolyl acetophenones: Discovery of positive allosteric potentiatiors for the metabotropic glutamate 2 receptor

被引:50
作者
Pinkerton, AB [1 ]
Vernier, JM [1 ]
Schaffhauser, H [1 ]
Rowe, BA [1 ]
Campbell, UC [1 ]
Rodriguez, DE [1 ]
Lorrain, DS [1 ]
Baccei, CS [1 ]
Daggett, LP [1 ]
Bristow, LJ [1 ]
机构
[1] Merck Res Labs, San Diego, CA 92121 USA
关键词
D O I
10.1021/jm040088h
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Herein we disclose the discovery of a new class of positive allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2), phenyl-tetrazolyl acetophenones, e.g. 1-(2-hydroxy-3-propyl-4-{4-[4-(2H-tetrazol-5-yl)phenoxy]butoxy}phenyl) ethanone (4). These potentiators were shown to have no effect in the absence of glutamate as well as no effect at mGlu3 or the other mGlu receptors. The compounds were also evaluated in rodent models with potential relevance for schizophrenia, and 4 was shown to have activity in the inhibition of ketamine-induced norepinephrine release and ketamine-induced hyperactivity. This represents the first example of the efficacy of mGlu2 receptor potentiators in these models.
引用
收藏
页码:4595 / 4599
页数:5
相关论文
共 22 条
[1]  
Cartmell J, 1999, J PHARMACOL EXP THER, V291, P161
[2]   Metabotropic Glutamate Receptors: Potential Drug Targets for the Treatment of Schizophrenia [J].
Chavez-Noriega, Laura E. ;
Schaffhauser, Herve ;
Campbell, Una C. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (03) :261-281
[3]   Pharmacology and functions of metabotropic glutamate receptors [J].
Conn, PJ ;
Pin, JP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :205-237
[4]   Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans [J].
Grillon, C ;
Cordova, J ;
Levine, LR ;
Morgan, CA .
PSYCHOPHARMACOLOGY, 2003, 168 (04) :446-454
[5]  
Helton DR, 1998, J PHARMACOL EXP THER, V284, P651
[6]   Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor:: Synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethyl-amine [J].
Johnson, MP ;
Baez, M ;
Jagdmann, GE ;
Britton, TC ;
Large, TH ;
Callagaro, DO ;
Tizzano, JP ;
Monn, JA ;
Schoepp, DD .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (15) :3189-3192
[7]   Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795 [J].
Kingston, AE ;
O'Neill, MJ ;
Lam, A ;
Bales, KR ;
Monn, JA ;
Schoepp, DD .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 377 (2-3) :155-165
[8]   Positive allosteric modulators of metabotropic glutamate 1 receptor: Characterization, mechanism of action, and binding site [J].
Knoflach, F ;
Mutel, V ;
Kew, JNC ;
Malherbe, P ;
Vieira, E ;
Wichmann, J ;
Kemp, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (23) :13402-13407
[9]   Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia [J].
Lam, AGM ;
Soriano, MA ;
Monn, JA ;
Schoepp, DD ;
Lodge, D ;
McCulloch, J .
NEUROSCIENCE LETTERS, 1998, 254 (02) :121-123
[10]  
Levine L, 2002, NEUROPHARMACOLOGY, V43, P294